Concepedia

Lu Xie

LX

Statistics

Publications

22

Citations

749

H-Index

14

Active since

2012

Affiliations

Peking University(Current)

Peking University People's Hospital

Peking University Shougang Hospital

Sun Yat-sen University

Sun Yat-sen University Cancer Center

Lu Xie is an author at Peking University specializing in medicine, oncology, and osteosarcoma treatment.

ORCID

Publications per year

2012–2024

22

Publications

22

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Lu Xie, Jie Xu, Xin Sun et al. · Journal for ImmunoTherapy of Cancer · 2020 · 150 citations · Full text

, , +12

Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial

Lu Xie, Jie Xu, Xin Sun et al. · The Oncologist · 2018 · 128 citations · Full text

, , +17

Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

Lu Xie, Wei Guo, Ye Wang et al. · BMC Cancer · 2018 · 63 citations · Full text

, , +14

Reconstruction of the hemipelvis with a modular prosthesis after resection of a primary malignant peri-acetabular tumour involving the sacroiliac joint

Jie Zang, Wei Guo, Yi Yang et al. · The Bone & Joint Journal · 2014 · 54 citations

, , +17

Pathologic fracture does not influence local recurrence and survival in high‐grade extremity osteosarcoma with adequate surgical margins

Lu Xie, Wei Guo, Yuanbo Li et al. · Journal of Surgical Oncology · 2012 · 43 citations

, , +17

1–5 of 22